Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records

CONCLUSION: These analyses support Dyanavel XR as a monotherapy for the daily management of ADHD in adults compared with other ER medications. Considering its tendency to reduce IR supplementation and its relationship with improved ADHD and anxiety symptoms, Dyanavel XR may simplify treatment regimens and improve outcomes.

via https://pubmed.ncbi.nlm.nih.gov/39754122/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20250110010905&v=2.18.0.post9+e462414